ROIV vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

ROIV

56.0
AI Score
VS
ROIV Wins

MRNA

51.3
AI Score

Investment Advisor Scores

ROIV

56score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ROIV MRNA Winner
Revenue 5.74M 534.00M MRNA
Net Income -602.76M -2.13B ROIV
Net Margin -10501.1% -397.9% MRNA
Operating Income -930.31M -2.20B ROIV
ROE -14.1% -31.4% ROIV
ROA -11.5% -19.4% ROIV
Total Assets 5.23B 10.96B MRNA
Cash 1.48B 1.72B MRNA
Current Ratio 30.66 2.29 ROIV
Free Cash Flow -593.48M -1.25B ROIV

Relative Price Performance (Last 90 Days)

ROIV 1M: -3.2% · 3M: +18.9% MRNA 1M: -24.4% · 3M: +19.3%

Current Technical Phase

ROIV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.7 · Price: $33.91

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 40.6 · Price: $54.82

Fundamentals Snapshot

Metric ROIV MRNA
Market Cap
Forward P/E -29.3 -11.5
Trailing P/E
Revenue (TTM)
Revenue Growth -0.7% 2.6%
Gross Margin -81.6% -0.7%
Operating Margin -146.8% -1.3%
EPS -0.57 -8.14
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ROIV is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.